Interleukin-1β induces ceruloplasmin and ferroportin-1 gene expression via MAP kinases and C/EBPβ, AP-1, and NF-κB activation

被引:36
|
作者
Persichini, Tiziana [1 ]
Maio, Nunziata [1 ]
di Patti, Maria Carmela Bonaccorsi [2 ]
Rizzo, Gianluca [1 ]
Colasanti, Marco [1 ]
Musci, Giovanni [1 ,3 ]
机构
[1] Univ Roma Tre, Dipartimento Biol, I-00146 Rome, Italy
[2] Univ Roma La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy
[3] Univ Molise, Dept STAAM, I-86100 Campobasso, Italy
关键词
Astrocyte; Ceruloplasmin; Ferroportin; Interleukin-1; beta; Iron; IRON EFFLUX; IN-VIVO; CELLS; INHIBITOR; PROMOTER; BINDING; IDENTIFICATION; ASTROCYTES; PATHWAY; SYSTEM;
D O I
10.1016/j.neulet.2010.08.034
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Previously, we demonstrated that IL-1 beta was able to increase iron efflux from glial cells through a coordinate induction of both ferroportin-1 (Fpn) and ceruloplasmin (Cp) synthesis. In this study, we have investigated the signaling pathways that are involved in the transcriptional activation of the Cp and Fpn. Our data show that the expression of Cp and Fpn in response to IL-1 beta requires the activation of MAP kinase pathways as a consequence of an IL-1 beta receptor stimulation. Moreover, we have observed that IL-1 beta regulates the expression of Cp and Fpn genes through (i) p38 MAPK-mediated activation of C/EBP transcription factor, (ii) ERK1/2-, JNK1- and partially p38 MAPK-dependent activation of AP-1, and through (iii) activation of NF-kappa B partially mediated by p38 MAPK. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:133 / 138
页数:6
相关论文
共 50 条
  • [41] Verotoxin-1 induces tissue factor expression in human umbilical vein endothelial cells through activation of NF-κB/Rel and AP-1
    Ishii, H
    Takada, K
    Higuchi, T
    Sugiyama, J
    THROMBOSIS AND HAEMOSTASIS, 2000, 84 (04) : 712 - 721
  • [42] Glucocorticoids augment the chemically induced production and gene expression of interleukin-lα through NF-κB and AP-1 activation in murine epidermal cells
    Miyazaki, Y
    Yokozeki, H
    Awad, S
    Igawa, K
    Minatohara, K
    Satoh, T
    Katayama, I
    Nishioka, K
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (04) : 746 - 752
  • [43] PHOTODYNAMIC THERAPY INDUCES EXPRESSION OF INTERLEUKIN-6 BY ACTIVATION OF AP-1 BUT NOT NF-KAPPA-B DNA-BINDING
    KICK, G
    MESSER, G
    GOETZ, A
    PLEWIG, G
    KIND, P
    CANCER RESEARCH, 1995, 55 (11) : 2373 - 2379
  • [44] Kinin B1 and B2 receptor expression in osteoblasts and fibroblasts is enhanced by interleukin-1 and tumour necrosis factor-α.: Effects dependent on activation of NF-κB and MAP kinases
    Brechter, Anna Bernhold
    Persson, Emma
    Lundgren, Inger
    Lerner, Ulf H.
    BONE, 2008, 43 (01) : 72 - 83
  • [45] Soluble transition metals in welding fumes cause inflammation via activation of NF-κB and AP-1
    McNeilly, JD
    Jiménez, LA
    Clay, MF
    MacNee, W
    Howe, A
    Heal, MR
    Beverland, IJ
    Donaldson, K
    TOXICOLOGY LETTERS, 2005, 158 (02) : 152 - 157
  • [46] Interleukin-1β enhances cell migration through AP-1 and NF-κB pathway dependent FGF2 expression in human corneal endothelial cells
    Sand, Daniel
    Lee, JeongGoo
    Heur, J.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [47] Role of nitric oxide in the activation of NF-κB, AP-1 and NOS II expression in articular chondrocytes
    A. F. Mendes
    A. P. Carvalho
    M. M. Caramona
    M. C. Lopes
    Inflammation Research, 2002, 51 : 369 - 375
  • [48] The cancer/testis antigen CAGE induces MMP-2 through the activation of NF-κB and AP-1
    Kim, Youngmi
    Jeoung, Dooil
    BMB REPORTS, 2009, 42 (11) : 758 - 763
  • [49] Injury induces alterations in T-cell NFκB and AP-1 activation
    O'Suilleabhain, CB
    Kim, SM
    Rodrick, MR
    Mannick, JA
    Lederer, JA
    SHOCK, 2001, 15 (06): : 432 - 437
  • [50] Impact of a phosphorothioate oligodeoxynucleotide MCP-1 on NF-κB, AP-1, SP1 and NF-κB, and AP-1 subunit composition in human pulmonary endothelial cells
    Maus, U
    Seeger, W
    Lohmeyer, J
    ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 2001, 11 (01): : 59 - 64